{"id":301,"date":"2015-05-13T14:37:24","date_gmt":"2015-05-13T21:37:24","guid":{"rendered":"http:\/\/www.iths.org\/v4-stage\/?page_id=94"},"modified":"2023-09-07T14:35:35","modified_gmt":"2023-09-07T21:35:35","slug":"patient-access","status":"publish","type":"page","link":"https:\/\/www.iths.org\/cpci\/activities\/patient-access\/","title":{"rendered":"Patient Access"},"content":{"rendered":"

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text]<\/p>\n

Expanding access to cell-based immunotherapeutics to ensure health equity.<\/h2>\n

[\/vc_column_text][vc_empty_space][\/vc_column][\/vc_row][vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text]A key challenge in treating pediatric populations with rare disease is ensuring equitable access of cellular immunotherapies to children, regardless of their site of primary medical care, racial, or socio-economic status. Clinical trial complexity may impede the enrollment of study participants if multiple clinical assessments or research visits are required, especially if study participants travel significant distances from their primary residence.<\/p>\n

The Patient Advocacy Committee of the Consortium is actively working to understand the pediatric immunotherapy patient population better. Through a retrospective study (see abstracts below), we will develop a more complete picture of who participates in immunotherapy trials.<\/p>\n

In addition, the committee, with the support of a supplemental grant (3U01TR002487-03S1<\/a>), is researching the many barriers to patient enrollment by conducting surveys and interviews with both patients\/caregivers and providers. Based on our learnings, we will be better able to suggest improvements to the enrollment process that will allow for greater patient access.<\/p>\n

Finally, more sites are adopting social media strategies to better reach patients, caregivers and providers in search of trial opportunities.[\/vc_column_text][vc_empty_space][button icon=”fa-arrow-circle-right” target=”_self” hover_type=”enlarge” text=”Learn more about clinical trials led by CPCI sites” link=”\/cpci\/?p=1049″][vc_empty_space][vc_column_text]<\/p>\n

Related Papers<\/h3>\n

<\/span>ASCO Abstract: Pediatric oncologist referral practices for CAR T-cell therapy: A mixed methods study<\/a><\/span>Transplant and Cellular Therapy Publication: Access to Chimeric Antigen Receptor T Cell Clinical Trials in Underrepresented Populations: A Multicenter Cohort Study of Pediatric and Young Adult Acute Lymphobastic Leukemia Patients<\/a><\/span>ASH Abstract: Access to CAR-T cell Therapy in Underrepresented Populations: a Multicenter Cohort Study of Pediatric and Young Adult ALL Patients<\/a><\/span>ASPHO Abstract: Equitable access to CAR-T cell therapy: an analysis of patient demographic and socioeconomic factors from cellular therapy trials at a single institution<\/a><\/p>\n